<DOC>
	<DOCNO>NCT01405053</DOCNO>
	<brief_summary>This study design evaluate cognitive effect , safety , pharmacokinetics ( PK ) rufinamide Lennox-Gastaut Syndrome inadequately control pediatric subject already take anti-epileptic drug .</brief_summary>
	<brief_title>Study Rufinamide Pediatric Subjects 1 Less Than 4 Years Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Lennox Gastaut Syndrome</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<criteria>Key Inclusion : 1 . Clinical diagnosis LGS screening , might include presence slow background electroencephalogram ( EEG ) rhythm , slow spikeswaves pattern ( less 3 Hz ) , presence polyspikes ; care take include benign myoclonic epilepsy infancy , subject diagnosis atypical benign partial epilepsy ( pseudoLennox syndrome ) , continuous spikewaves slow sleep ( CSWS ) . 2 . On fix dose one three concomitant regionally approve antiepileptic drug ( AEDs ) minimum 8 week prior randomization inadequate response treatment . 3 . Consistent seizure documentation ( i.e. , uncertainty presence seizure ) AED treatment documentation 8 week prerandomization period . Key Exclusion : 1 . Familial short QT syndrome 2 . Prior treatment rufinamide</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>3 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Central Nervous System</keyword>
</DOC>